Hims and Hers Missed Q1. Then Raised Guidance. Here Is Why the Story Is Just Starting.

She missed Q1. Then raised guidance. The Novo Nordisk deal is why. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  

May 12, 2026 Hims and Hers Missed Q1. Then Raised Guidance. Here Is Why the Story Is Just Starting. Hims & Hers Health (HIMS) reported Q1 2026 earnings on May 11 and the stock dropped. Revenue of $608.1 million missed estimates. The GAAP loss came in at $0.40 per share. On the surface, it looks like a mess. But the surface is the wrong place to look. The miss was a deliberate transition. In March 2026, Hims & Hers settled its lawsuit with Novo Nordisk and agreed to stop advertising compounded GLP-1 drugs. In exchange, it gained access to sell branded Wegovy and Ozempic, including a new oral Wegovy pill, directly through its telehealth platform. Q1 captured only one week of that new lineup at lower margins. That explains the numbers. Despite the miss, the company raised full-year 2026 guidance to $2.8 billion to $3.0 billion. J.P. Morgan initiated coverage with an Overweight rating and a $35 price target, calling the Novo Nordisk deal a turning point. The stock is trading near $29, down 58% from its 52-week high of $70.43. The pivot is messy. The setup is real. Read the full analysis › Turn Your 401k Into Real Gold Sponsored Discover how people with 401(k)s and IRAs are exploring ways to move a portion of their retirement savings into real, tangible assets like physical gold. Learn the rules, options, and common mistakes to avoid with the Bulletproof Retirement Kit. Unlock the step-by-step plan. › You are receiving this e-mail at reditudo@gmail.com, as part of your subscription to Money Morning. Manage Your Preferences by clicking here. No longer interested? Unsubscribe. © 2026 Money Morning. All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of: Agora Media, 14 West Mt Vernon Place, Baltimore, MD 21201. Money Morning is a First Light Financial, LLC publication. To contact us call 866-616-2166 or visit us online. Website | Privacy Policy | Terms & Conditions